Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
Brief Summary: The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Options:
A: Arm Label: albiglutide + metformin; Type: EXPERIMENTAL; Interventions: Biological: albiglutide, Drug: metformin, Drug: placebo sitagliptin, Drug: placebo glimepiride | Arm Label: sitagliptin + metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: metformin, Biological: placebo albiglutide, Drug: placebo glimepiride | Arm Label: glimepiride + metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: metformin, Biological: placebo albiglutide, Drug: placebo sitagliptin | Arm Label: metformin + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Biological: placebo albiglutide, Drug: placebo sitagliptin, Drug: placebo glimepiride | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide + metformin | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): sitagliptin + metformin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride + metformin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): albiglutide + metformin, glimepiride + metformin, metformin + placebo, sitagliptin + metformin | Intervention Type: BIOLOGICAL; Name: placebo albiglutide; Assigned to Arm(s): glimepiride + metformin, metformin + placebo, sitagliptin + metformin | Intervention Type: DRUG; Name: placebo sitagliptin; Assigned to Arm(s): albiglutide + metformin, glimepiride + metformin, metformin + placebo | Intervention Type: DRUG; Name: placebo glimepiride; Assigned to Arm(s): albiglutide + metformin, metformin + placebo, sitagliptin + metformin
B: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
C: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Linagliptin Placebo | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Linagliptin Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
D: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo (high dose) | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo (low dose), Drug: BI 10773 | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo (low dose); Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo (high dose); Assigned to Arm(s): BI 10773 low dose

Answer: D